09:58 AM EDT, 07/05/2024 (MT Newswires) -- Ascendis Pharma ( ASND ) and Pendopharm have signed a distribution agreement under which the latter will oversee regulatory approval and commercialization of Ascendis' hypoparathyroidism treatment TransCon parathyroid hormone, or PTH, in Canada, Pendopharm said Thursday.

Financial terms of the agreement weren't disclosed.

TransCon PTH is a parathyroid hormone replacement therapy for chronic hypoparathyroidism, a condition due to the absence or insufficient levels of PTH, Pendopharm added.

TransCon is approved in the EU, European Economic Area, and Great Britain under the Yorvipath brand name, Pendopharm said.

Pendopharm is a division of Canadian specialty pharmaceutical firm, Pharmascience.

Price: 134.46, Change: +0.28, Percent Change: +0.21